Healthcare Stock Performance Review -- Brookdale Senior Living, BioScrip, Envision Healthcare, and Kindred Healthcare

Wednesday, June 14, 2017 Senior Health News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, June 14, 2017 /PRNewswire/ -- navigates the Healthcare sector, which is an aggregation

and integration of sectors within the economic system that provides goods and services to treat patients with curative, preventive, rehabilitative, and palliative care. Equities for evaluation are Brookdale Senior Living Inc. (NYSE: BKD), BioScrip Inc.
(NASDAQ: BIOS), Envision Healthcare Corp. (NYSE: EVHC), and Kindred Healthcare Inc. (NYSE: KND). These free stocks reports are currently available on Simply sign up for your complimentary member access at:

Brookdale Senior Living 

Brentwood, Tennessee headquartered Brookdale Senior Living Inc.'s stock finished Tuesday's session 2.90% lower at $14.07. A total volume of 10.07 million shares was traded, which was above their three months average volume of 2.79 million shares. Over the previous three months and since the start of this year, the Company's shares have advanced 15.14% and 13.29%, respectively. The stock is trading above its 50-day moving average by 4.08%. Moreover, shares of Brookdale Senior Living, which owns and operates senior living communities in the US, have a Relative Strength Index (RSI) of 53.70. Your complete research report on BKD can be retrieved for free at:


Shares in Denver, Colorado-based BioScrip Inc. rose 0.41%, ending yesterday's session at $2.43 with a total trading volume of 1.33 million shares. The stock has surged 40.46% in the past month, 21.50% in the previous three months, and 133.65% on an YTD basis. The Company's shares are trading 43.46% above their 50-day moving average and 28.77% above their 200-day moving average. Moreover, shares of BioScrip, which provides home infusion services in the US, have an RSI of 89.29.

On May 30th, 2017, BioScrip announced that the Company has reached an agreement to continue to provide certain core product lines to UnitedHealthcare beyond September 30th, 2017. With this agreement, the former will retain approximately $35 million of annualized profitable core revenue. A free report on BIOS is just a click away at:

Envision Healthcare 

On Tuesday, Nashville, Tennessee-based Envision Healthcare Corp.'s stock saw a slight decline of 0.39%, to close the day at $56.73. A total volume of 980,088 shares was traded. The Company's shares have advanced 0.28% in the last month. The stock is trading 0.53% below its 50-day moving average. Additionally, shares of Envision Healthcare, which through its subsidiaries, provides various healthcare services in the US, have an RSI of 52.61.

On May 30th, 2017, research firm Mizuho reiterated its 'Neutral' rating on the Company's stock with a decrease of the target price from $70 a share to $60 a share.

On June 08th, 2017, Envision Healthcare announced that its management will present at the William Blair 2017 Growth Stock Conference on Wednesday, June 14th, 2017, in Chicago, Illinois. In connection with the conference, there will be an on-line simulcast and a replay of the presentation available starting at 1:00 p.m. ET on the Company's website. Sign up for your complimentary research report on EVHC at:

Kindred Healthcare 

Shares in Louisville, Kentucky headquartered Kindred Healthcare Inc. ended the day 2.36% higher at $10.85. A total volume of 809,897 shares was traded. The stock has gained 0.46% in the last one month, 33.95% in the previous three months, and 38.22% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 13.99% and 24.74%, respectively. Furthermore, shares of Kindred Healthcare, which provides healthcare services in the US, have an RSI of 62.98.  

On May 30th, 2017, Kindred Healthcare announced the appointment of Brian Holzer, M.D. as President of Kindred Innovations. Dr. Holzer will report to Benjamin A. Breier, President and CEO, and will work closely with Executive Vice President and Chief Strategy Officer William Altman, who will continue to oversee the Company's enterprise strategic plan. Mr. Altman will take on the additional responsibility as Chief of Staff to Mr. Breier. Register for free on and download the latest research report on KND at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store